Tuberculosis vaccine development :The development of a novel (preclinical) DNA vaccine

Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models

“…15 Aeras-402 DNA (DNA that expressed 85A, 85B and TB10.4) vaccine using adenovirus vector is intended for use as a boosting vaccine in BCG-primed individuals. 16 Several vaccines use a prime-boost strategy to enhance the immune responses. 17 In Japan and other countries, the BCG vaccine is inoculated into human infants (0-6 months after birth).…”

DNA Vaccines: How Much Have We Accomplished In The Last 25 Years?

“…This approach was used successfully against Mycobacterium tuberculosis [106], Yersinia pestis [107,108], HIV [3,109], cytomegalovirus [110], and tumors [111]. The coadministration of plasmids encoding IL-12 and IL-15 in macaques increased the specific CD8 + T cell memory populations and their ability to produce cytokines [112].…”

Molecular Cloning, Expression, Purification and Immunological Characterization of Proteins Encoded by Regions of Difference Genes of Mycobacterium tuberculosis

“…Besides, it is generally believed that novel TB vaccines will be tested in the context of the widely used BCG and perhaps different kinds of vaccines are needed for the eradication of TB (Mitsuyama & McMurray, 2007;Sander & McShane, 2007). As a result, enhancement of TB DNA vaccine efficacy has become the active field of current research (Okada & Kita, 2010). In this context, Baldwin et al have shown that inclusion of the secretion signal peptide from tissue plasminogen activator (tPA) into a DNA vaccine construct resulted in stronger immune responses to Ag85A, and provided sustained protection upon M. tuberculosis challenge in mice, as compared to the DNA vaccine construct based on the parent plasmid lacking tPA (Baldwin et al, 1999).…”